Lori O'Toole
Cardiovascular Disease · Las Vegas, NVNPI 1023355179
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,247 of the $8,249 with a category attached, or 87.8%. It is spread thinly across 31 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,885 and has fallen 82.5% since, to $506 in 2025.
Across 198 payments — averaging $41.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$1K
- AstraZeneca$1K
- Novartis$892
- Johnson & Johnson$838
- Boehringer Ingelheim$795
- Novo Nordisk$614
- plus $3K from 25 others
What the payments were for
- Consulting fees$92811%
- Food & beverage$7,24788%
- Education$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 3 | $1,146 |
| AstraZeneca | 12 | $1,045 |
| Novartis | 43 | $892 |
| Johnson & Johnson | 29 | $838 |
| Boehringer Ingelheim | 17 | $795 |
| Novo Nordisk | 14 | $614 |
| Esperion Therapeutics, Inc. | 8 | $514 |
| Merck | 16 | $428 |
| Daiichi Sankyo Inc. | 9 | $382 |
| Lilly USA, LLC | 4 | $169 |
| Abbott | 2 | $166 |
| Amgen | 11 | $138 |
| Mannkind Corporation | 1 | $125 |
| GSK | 2 | $122 |
| Idorsia Pharmaceuticals US Inc | 2 | $122 |
| Argenx US, Inc. | 1 | $120 |
| Ultragenyx Pharmaceutical Inc. | 1 | $102 |
| Biogen | 1 | $92 |
| E.r. Squibb & Sons, L.L.C. | 4 | $88 |
| Edwards Lifesciences | 3 | $61 |
| Currax Pharmaceuticals LLC | 1 | $53 |
| Kowa Pharmaceuticals America, Inc. | 3 | $38 |
| Impulse Dynamics (USA) Inc. | 2 | $34 |
| Corcept Therapeutics | 2 | $31 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Astellas Pharma US Inc | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| Boston Scientific | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,249 in reported general payments places this provider in the 70th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Las Vegas
- Arjun GururajLas Vegas$399K
- Branavan UmakanthanLas Vegas$109K
- Jawad KianiLas Vegas$73K
- Amish PrasadLas Vegas$58K
- Chowdhury AhsanLas Vegas$41K
- Sanjay MalhotraLas Vegas$41K
- William ReshLas Vegas$39K
- Ali NamaziLas Vegas$38K
- Herbert Cordero YordanLas Vegas$38K
- Alfred DanielianLas Vegas$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.